Diagnostic yield of endoscopic ultrasonography in patients with intermediate or high likelihood of choledocholithiasis: a retrospective study from one university-based endoscopy center

Table 2 Univariate analyses of factors potentially associated with detection of CBD stones

	No CBD stone detected (n = 65)	CBD stone detected (n = 28)	p value
Mean (±SD) age (years)	58.85 (±16.09)	65.26 (±13.76)	0.06
Mean (±SD) alkaline phosphatase level (U/mL)	147.40 (±127.55)	226.30 (±192.64)	0.02*
Mean (±SD) total bilirubin level (mg/dL)	3.19 (±5.20)	2.57 (±2.33)	0.54
Mean (±SD) SGOT level (U/L)	215.13 (±176.86)	215.13 (±250.75)	0.13
Mean (±SD) SGPT level (U/L)	137.07 (±210.94)	198.65 (±184.04)	0.17
Clinical classification			0.06
Intermediate likelihood (n = 49)	38	11
High likelihood (n = 44)	27	17
Dilated CBD on transabdominal
ultrasonography (n = 26)	5	21	0.48
Mean (±SD) time interval (days)	38.95 (±62.77)	33.23 (±42.24)	0.64
EUS performed within 7 days (n)	14	14	0.02*

CBD common bile duct, EUS endoscopic ultrasonography, ERCP endoscopic retrograde cholangiopancreatography, SGOT serum glutamic-oxaloacetic transaminase, SGPT serum glutamic-pyruvic transaminase.